LONDON and SALT LAKE CITY, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that Ann Berman, non-executive director and chair of the audit and nomination committees, has resigned as a director of the Company for personal reasons effective immediately. Ms.
RNS Number : 9534Z Renalytix PLC 20 September 2022 Renalytix plc ("Renalytix" or the "Company") Renalytix Announces Change to Board of Directors LONDON and SALT LAKE CITY , 20 September 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that Ann Berman , non-executive director
RNS Number : 0215Z Renalytix PLC 12 September 2022 Renalytix plc ("Renalytix" or the "Company") Issue of shares NEW YORK and SALT LAKE CITY , 12 September, 2022 - Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"),
NEW YORK and SALT LAKE CITY, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the company will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022.
RNS Number : 6200Y Renalytix PLC 08 September 2022 Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference NEW YORK, NY and SALT LAKE CITY, UT ̶ September 8, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the company will participate in a
RNS Number : 3072W Renalytix PLC 17 August 2022 This contains inside information Renalytix plc ("Renalytix" or the "Company") Business update NEW YORK, NY and SALT LAKE CITY, UT August 17, 2022 (GLOBE NEWSWIRE) - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) provides the following business
98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with type 2 diabetes and chronic kidney disease stages 1-3b. Published study complements KidneyIntelX clinical utility data published at American Diabetes Association Annual
RNS Number : 1019V Renalytix PLC 08 August 2022 Renalytix plc ("Renalytix" or the "Company") Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX TM with Primary Care Physicians 98% of 401 Primary Care Physicians confirmed
LONDON and SALT LAKE CITY, June 30, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today
RNS Number : 7475Q Renalytix PLC 30 June 2022 Renalytix plc ("Renalytix" or the "Company") Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022 LONDON and SALT LAKE CITY , June 30, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in
